Alefacept
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Moderate to Severe Chronic Plaque Psoriasis
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Trial Timeline
Jul 1, 2004 → Mar 1, 2005
NCT ID
NCT00168753About Alefacept
Alefacept is a approved stage product being developed by Astellas Pharma for Moderate to Severe Chronic Plaque Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00168753. Target conditions include Moderate to Severe Chronic Plaque Psoriasis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01267643 | Phase 1 | Terminated |
| NCT01226420 | Phase 2 | Terminated |
| NCT00808223 | Phase 2 | Completed |
| NCT00815633 | Approved | Terminated |
| NCT00953329 | Approved | Terminated |
| NCT00832585 | Approved | Completed |
| NCT00658606 | Approved | Completed |
| NCT00168753 | Approved | Completed |
| NCT00674063 | Phase 3 | Completed |
| NCT00692172 | Phase 3 | Completed |
Competing Products
20 competing products in Moderate to Severe Chronic Plaque Psoriasis